产品: 磷酸化 MYPT1 (Ser472) 抗体
货号: AF3779
描述: Rabbit polyclonal antibody to Phospho-MYPT1 (Ser472)
应用: WB
文献验证: WB
反应: Human, Mouse, Rat
蛋白号: O14974
RRID: AB_2847093

浏览相似产品>>

   规格 价格 库存
 100ul RMB¥ 2800 现货
 200ul RMB¥ 3800 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Phospho-MYPT1 (Ser472) Antibody detects endogenous levels of MYPT1 only when phosphorylated at Ser472.
RRID:
AB_2847093
引用格式: Affinity Biosciences Cat# AF3779, RRID:AB_2847093.
偶联:
Unconjugated.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

M130; MBS; Myosin binding subunit; Myosin phosphatase target subunit 1; Myosin phosphatase targeting subunit 1; Myosin phosphatase-targeting subunit 1; MYPT1; MYPT1_HUMAN; PPP1R12A; Protein phosphatase 1 regulatory inhibitor subunit 12A; Protein phosphatase 1 regulatory subunit 12A; Protein phosphatase 1, regulatory (inhibitor) subunit 12A; Protein phosphatase myosin binding subunit; Protein phosphatase myosin-binding subunit;

抗原和靶标

免疫原:

A synthesized peptide derived from human MYPT1 around the phosphorylation site of Ser472.

基因/基因ID:

研究领域

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Organismal Systems > Circulatory system > Vascular smooth muscle contraction.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

文献引用

1). AMPK is a mechano-metabolic sensor linking cell adhesion and mitochondrial dynamics to Myosin-dependent cell migration. Nature Communications, 2023 (PubMed: 37217519) [IF=16.6]

Application: WB    Species: Human    Sample: A375P cells

Fig. 4: ATP levels control plasticity of cell migration through AMPK. a AMP, ATP/AMP and ATP/ADP in A375P cells treated with rotenone (0.5 μM) and antimycin A (0.5 μM) (5 replicates/condition). b Western blot for the same conditions as in (a). c Western blot of the indicated proteins (WM983 n = 6, A375 n = 5). d Western blot upon AMPK knock-down (n = 3). e Cells grown on a collagen I matrix. Immunofluorescence images showing pMLC2 (green) and F-actin (red) (n = 3). Scale bar = 5 μm. f–h Quantification of cell morphology (211, 193 cells pooled from n = 3) (f), pMLC2 immunofluorescence signal normalized by cell area (52, 66 cells pooled from n = 3) (g) and representative traction stress (n = 3). Colour bar indicates traction stress magnitude (Pascal, Pa), scale bar = 20 μm (h). i Western blot upon AMPK activation (A769662 10 μM, 30 minutes) (n = 5). j–l Cells grown on a collagen I matrix. Immunofluorescence images showing pMLC2 (green) and F-actin (red) after A769662 treatment (10 μM, 24 h) (n = 3), scale bar = 10 μm (j); quantification of cell morphology (317, 283 cells pooled from n = 3) (k) and quantification of pMLC2 immunofluorescence signal normalized by cell area (81, 84 cells pooled from n = 3) (l). m, n Western blot and quantification after DDR1 knock-down and Comp C treatment (2 μM, 24 h) (n = 8 AMPK, n = 6 ACC, n = 9 MYPT1). o–q Cells grown on a collagen I matrix. Immunofluorescence images showing pMLC2 (green) and F-actin (red) (n = 3), scale bar = 10 μm (o); quantification of cell morphology (274, 210, 274, 191 cells pooled from n = 3) (p) and quantification of pMLC2 immunofluorescence signal normalized by cell area (93, 84, 94, 93 cells pooled from n = 3) (q). Quantification versus corresponding total protein (b, c, d, i). Graphs (a, n) show mean ± SEM. Violin plots (f, k, p) show median with interquartile range. Box plots (g, l, q) show median (centre line), interquartile range (box) and min-max values (whiskers). p values were calculated using two-tailed tests (f, g, k, l). p value by Mann–Whitney test (f, g, k, l), one-way ANOVA with Dunnett’s correction (a) or Tukey’s multiple test (n) and Kruskal-Wallis with Dunn’s multiple comparisons test (p, q). All n are indicative of independent experiments unless otherwise stated. Source data are provided as a Source Data file.

Application: WB    Species: Human    Sample: A375P cells

Fig. 4: ATP levels control plasticity of cell migration through AMPK. a AMP, ATP/AMP and ATP/ADP in A375P cells treated with rotenone (0.5 μM) and antimycin A (0.5 μM) (5 replicates/condition). b Western blot for the same conditions as in (a). c Western blot of the indicated proteins (WM983 n = 6, A375 n = 5). d Western blot upon AMPK knock-down (n = 3). e Cells grown on a collagen I matrix. Immunofluorescence images showing pMLC2 (green) and F-actin (red) (n = 3). Scale bar = 5 μm. f–h Quantification of cell morphology (211, 193 cells pooled from n = 3) (f), pMLC2 immunofluorescence signal normalized by cell area (52, 66 cells pooled from n = 3) (g) and representative traction stress (n = 3). Colour bar indicates traction stress magnitude (Pascal, Pa), scale bar = 20 μm (h). i Western blot upon AMPK activation (A769662 10 μM, 30 minutes) (n = 5). j–l Cells grown on a collagen I matrix. Immunofluorescence images showing pMLC2 (green) and F-actin (red) after A769662 treatment (10 μM, 24 h) (n = 3), scale bar = 10 μm (j); quantification of cell morphology (317, 283 cells pooled from n = 3) (k) and quantification of pMLC2 immunofluorescence signal normalized by cell area (81, 84 cells pooled from n = 3) (l). m, n Western blot and quantification after DDR1 knock-down and Comp C treatment (2 μM, 24 h) (n = 8 AMPK, n = 6 ACC, n = 9 MYPT1). o–q Cells grown on a collagen I matrix. Immunofluorescence images showing pMLC2 (green) and F-actin (red) (n = 3), scale bar = 10 μm (o); quantification of cell morphology (274, 210, 274, 191 cells pooled from n = 3) (p) and quantification of pMLC2 immunofluorescence signal normalized by cell area (93, 84, 94, 93 cells pooled from n = 3) (q). Quantification versus corresponding total protein (b, c, d, i). Graphs (a, n) show mean ± SEM. Violin plots (f, k, p) show median with interquartile range. Box plots (g, l, q) show median (centre line), interquartile range (box) and min-max values (whiskers). p values were calculated using two-tailed tests (f, g, k, l). p value by Mann–Whitney test (f, g, k, l), one-way ANOVA with Dunnett’s correction (a) or Tukey’s multiple test (n) and Kruskal-Wallis with Dunn’s multiple comparisons test (p, q). All n are indicative of independent experiments unless otherwise stated. Source data are provided as a Source Data file.

2). AMPK is a Mechano-Metabolic Sensor Linking Mitochondrial Dynamics to Myosin II Dependent Cell Migration. , 2021

3). AMPK is a mechano-metabolic sensor linking cell adhesion and mitochondrial dynamics to Myosin II dependent cell migration. , 2022

Application: WB    Species: Mouse    Sample: WM983B and A375M2 cells

Figure 4: Energy levels control plasticity of cell migration through AMPK signalling. A-B) Western blot (A) and quantification (B) of AMPK and MYPT1 phosphorylation in rounded-amoeboid versus elongated-mesenchymal cells (n=3). C) Upon AMPK inhibition (Compound C (Comp C) 2 mM, 24 hours) in WM983B and A375M2 cells, western blot showing levels of AMPK and MYPT1 phosphorylation (n=3). Quantification normalized by total AMPK and MYPT1, respectively. D) Cells grown on a collagen I matrix. Immunofluorescence images showing pMLC2 (green) and F-actin (red) after Comp C treatment (2 mM, 24 hours). Scale bar = 10 mm. E-F) After Comp C treatment, quantification of cell morphology (>200 cells pooled from 3 experiments) (E) and quantification of pMLC2 immunofluorescence signal normalized by cell area (>90 cells pooled from 3 experiments) (F). G) Upon AMPK activation (A769662 10 mM, 30 minutes) in WM983A and A375P cells, western blot showing levels of AMPK and MYPT1 phosphorylation (n=3). Quantification normalized by total AMPK and MYPT1, respectively. H) Cells grown on a collagen I matrix. Immunofluorescence images showing pMLC2 (green) and F-actin (red) after A769662 treatment (10 mM, 24 hours). Scale bar = 10 mm. I-J) After A769662 treatment, quantification of cell morphology (>200 cells pooled from 3 experiments) (I) and quantification of pMLC2 immunofluorescence signal normalized by cell area (>90 cells pooled from 3 experiments) (J). K-L) Western blot (K) and quantification (L) of AMPK and MYPT1 phosphorylation levels after DDR1 knockdown and treatment with Comp C (2 mM, 24 hours) in A375P cells (n=3). M) Cells grown on a collagen I matrix. Immunofluorescence images showing pMLC2 (green) and F-actin (red) after DDR1 knock-down and Comp C treatment (2 mM, 24 hours). Scale bar = 10 mm. N-O) After DDR1 knock-down and Comp C treatment, quantification of cell morphology (>200 cells pooled from 3 experiments) (N) and quantification of pMLC2 immunofluorescence signal normalized by cell area (>90 cells pooled from 3 experiments) (O). Graphs (B, L) show mean ± SEM. Dot plots (E, I, N) show median with interquartile range (each dot represents a single cell). Box plots (F, J, O) show min to max. p value by paired t-test (B), Mann-Whitney test (E, F, I, J), one-way ANOVA with Dunnett’s correction (L) and Kruskal-Wallis with Dunn’s multiple comparisons test (N, O). For all graphs, *p

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.